Share on StockTwits

Agios Pharmaceuticals (NASDAQ:AGIO) COO John Duncan Higgons unloaded 5,000 shares of the stock on the open market in a transaction dated Friday, June 13th. The shares were sold at an average price of $45.27, for a total value of $226,350.00. Following the completion of the sale, the chief operating officer now directly owns 188,090 shares of the company’s stock, valued at approximately $8,514,834. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link.

A number of research firms have recently commented on AGIO. Analysts at JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Agios Pharmaceuticals in a research note on Monday. They now have a $60.00 price target on the stock, up previously from $55.00. Separately, analysts at Zacks upgraded shares of Agios Pharmaceuticals from an “underperform” rating to a “neutral” rating in a research note on Tuesday, May 6th. They now have a $44.80 price target on the stock. Finally, analysts at Leerink Swann raised their price target on shares of Agios Pharmaceuticals from $51.00 to $65.00 in a research note on Monday, April 7th. One investment analyst has rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $51.70.

Agios Pharmaceuticals (NASDAQ:AGIO) traded down 0.48% during mid-day trading on Monday, hitting $47.27. 659,563 shares of the company’s stock traded hands. Agios Pharmaceuticals has a one year low of $15.77 and a one year high of $49.79. The stock has a 50-day moving average of $38.62 and a 200-day moving average of $33.87. The company’s market cap is $1.605 billion.

Agios Pharmaceuticals (NASDAQ:AGIO) last announced its earnings results on Thursday, May 8th. The company reported ($0.39) EPS for the quarter, missing the Thomson Reuters consensus estimate of ($0.38) by $0.01. On average, analysts predict that Agios Pharmaceuticals will post $-1.47 earnings per share for the current fiscal year.

Agios Pharmaceuticals, Inc is a biopharmaceutical company. The Company is intend to apply its deep understanding of metabolism, coupled with the Company’s ability to create medicines that can inhibit or activate metabolic enzymes, to fundamentally change the way cancer and inborn errors of metabolism (NASDAQ:AGIO) are treated.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.